Latest News and Press Releases

CAMBRIDGE, Mass., May 03, 2022 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a gene therapy company developing life-changing treatments and next-generation adeno-associated virus...

CAMBRIDGE, Mass., March 22, 2022 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a gene therapy company developing life-changing treatments and next-generation adeno-associated virus...

License option agreement with Novartis for target-specific access to TRACER™ next-generation AAV capsids for potential use with three CNS targets plus options to access capsids for two additional...

Voyager receives $54 million upfront with potential option exercise fees and milestone payments of up to $1.7 billion plus product sales-based royalties Novartis receives target-specific access to...

CAMBRIDGE, Mass., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR) a gene therapy company developing life-changing treatments and next-generation adeno-associated virus...

Accomplished drug developer to help further long-term strategy, external scientific and business collaborations Robin Swartz promoted to chief operating officer CAMBRIDGE, Mass., Feb. ...

Novel intravenous (IV) vectorized antibody approach designed to activate innate immune system, destroy metastatic breast cancer tumors, and inhibit tumor progression in CNS Proprietary...

CAMBRIDGE, Mass., Nov. 16, 2021 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a gene therapy company developing life-changing treatments and next-generation adeno-associated virus...

License option agreement with Pfizer provides Voyager $30M up front and up to $600M in potential exercise fees and milestone payments plus royalties in exchange for access to TRACER™ novel capsids for...

CAMBRIDGE, Mass., Oct. 20, 2021 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a gene therapy company developing life-changing treatments and next-generation adeno-associated virus...